Heron Therapeutics (HRTX) CFO Ira Duarte Sells $1.4K of Stock

Ira Duarte, the Executive Vice President and Chief Financial Officer of Heron Therapeutics, Inc. (NasdaqCM: HRTX), sold 3,555 shares of the company on June 16, 2026. The shares were sold at an average price of $0.38 each, amounting to a total transaction value of $1,350.90. This transaction was not part of a pre-arranged trading plan.

Insider Buying and Selling at Heron Therapeutics, Inc.

On June 16, 2026, Ira Duarte executed a sale of 3,555 shares at $0.38 per share without a pre-arranged plan. Additionally, on the same day, Duarte bought 12,500 shares, although the price for this transaction was not specified. William Forbes, EVP and Chief Development Officer, also bought 12,500 shares on June 6, 2026, while Mark Earl Hensley, Chief Operating Officer, sold 125,000 shares on May 6, 2026.

Other Institutional Activity in Heron Therapeutics

Rubric Capital Management LP held its position steady with 30,046,828 shares valued at about $24.0 million. BlackRock, Inc. reduced its stake by 111,814 shares, ending with 10,106,422 shares worth approximately $8.1 million. OrbiMed Advisors LLC made a significant move by adding 9,816,940 shares, reaching a total of 9,816,940 shares valued at $7.9 million. Vanguard Capital Management LLC also increased its holdings by 7,810,329 shares, holding a total of 7,810,329 shares valued at $6.2 million.

Heron Therapeutics, Inc. Stock Up 25.9%

Shares of Heron Therapeutics, Inc. (NasdaqCM: HRTX) traded at $0.38. The company has a market capitalization of approximately $71.9 million and a beta of 1.572, indicating higher volatility compared to the market. The stock's 52-week range is between $0.38 and $2.30, with a 50-day moving average of $0.87 and a 200-day moving average of $1.12. Heron has a current ratio of 2.53 and a quick ratio of 1.419, but a high debt-to-equity ratio of 1550.115.

Recent Earnings

Heron Therapeutics reported revenue of $150.7 million, although it experienced a revenue decline of 10.8%. The company's net margin was negative at -20.53%, reflecting ongoing financial challenges. The next earnings report is scheduled for August 7, 2026.

Analysts Set New Price Targets

On June 3, 2026, HC Wainwright & Co. maintained its 'buy' rating for Heron Therapeutics with a price target of $2.00. The consensus among two analysts is a 'buy' rating, with a mean target price of $3.00.

About Heron Therapeutics

Heron Therapeutics, Inc. is a biotechnology company based in Cary, North Carolina. It focuses on developing and commercializing therapies that improve medical care using its proprietary Biochronomer drug delivery technology. The company offers products like SUSTOL and CINVANTI for chemotherapy-induced nausea and vomiting, and is developing ZYNRELEF for pain management. Heron was founded in 1983 and is led by CEO Craig Alexander Collard.

Bottom Line

Ira Duarte's recent stock sale at Heron Therapeutics is part of regular insider activity. Heron Therapeutics, a biotechnology firm, has a diverse product pipeline aimed at enhancing patient care. Investors often watch these insider transactions and analyst ratings for insights, but it's important to remember that 13F filings and insider reports are backward-looking and may not reflect current positions.